FTHNasdaqPharmaceutical PreparationsUS GAAP · USD

Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing cancer therapies that target tumor metabolism and signaling pathways. Its lead program, PIKTOR, is an all-oral combination of serabelisib and sapanisertib designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway.

Kysy yhtiöstä
Liikevoitto (EBIT)−22,3milj. USD
+31,7 %v/v
Nettotulos−21,1milj. USD
+30,1 %v/v
Vapaa kassavirta−20,5milj. USD
+17,5 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−60−40−200milj. USD2020: EBIT −19 milj. USD20202021: EBIT −37 milj. USD20212022: EBIT −50 milj. USD20222023: EBIT −37 milj. USD20232024: EBIT −33 milj. USD20242025: EBIT −22 milj. USD2025−22
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Faeth Therapeutics, Inc.

Liiketoiminta

Osuus liikevaihdosta
Clinical-stage oncology therapeutics100 %

Investigational cancer drug candidates being advanced through clinical trials.

Asiakkaat

Faeth does not sell commercial products today; its direct counterparties are clinical investigators, trial sites, contract research organizations, and manufacturing partners that support development. If approved, its end customers would be physicians, hospitals, cancer centers, patients, and third-party payors in oncology markets.

Clinical development partners

CROs, investigators, and CMOs that execute trials and supply manufacturing for product candidates.

Oncology physicians and cancer centers

Future prescribers and treatment centers that would adopt approved therapies if clinical data support use.

Patients with advanced solid tumors

Patients in indications such as endometrial and HR+/HER2- breast cancer targeted by the pipeline.

Third-party payors

Payers that would determine reimbursement and access after regulatory approval.

Strategia

The company’s strategy is to advance PIKTOR through clinical trials and build evidence in specific oncology indications, including endometrial cancer and HR+/HER2- breast cancer. Longer term, it will need either internal commercialization capabilities or external partnerships to market any approved product.

Advance PIKTOR clinical developmentLyhyt aikaväli

Clinical data are the main value driver for a clinical-stage biotech with no product revenue.

Secure commercialization pathwayKeskipitkä aikaväli

Any approved product will require sales, marketing, and distribution capabilities or partners.

Broaden oncology pipelinePitkä aikaväli

A broader pipeline can diversify scientific risk and improve long-term optionality.

Maantiede

Faeth is headquartered in the United States and conducts its development activities through a U.S.-based biotechnology structure. Its clinical and regulatory exposure is centered on the U.S. FDA, while future commercialization could extend to overseas markets if products are approved.

Riskit

Faeth faces the classic risks of a clinical-stage biotech: trial failure, regulatory delay, and uncertainty around market acceptance even if approval is achieved. It also depends on third parties for manufacturing, raw materials, and commercialization, which creates supply-chain and execution risk across the development cycle.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Clinical development failure1Regulatory approval risk2Commercialization execution risk3Supplier and manufacturing dependence4China supply-chain exposure5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Clinical development failureVaikutus: KorkeaTodennäköisyys: Korkea

    Drug candidates may not show sufficient efficacy or safety in trials, which can end programs.

    Kohdistuu: PIKTOR and other oncology candidates

  2. Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    FDA or other regulators may require additional data, delay review, or reject applications.

    Kohdistuu: All product candidates

  3. Commercialization execution riskVaikutus: KorkeaTodennäköisyys: Matala

    The company may not build internal sales and marketing capabilities or secure effective partners.

    Kohdistuu: Future approved products

  4. Supplier and manufacturing dependenceVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Clinical materials and specialty inputs are sourced through third parties with limited redundancy.

    KohdistuuReagentsSpecialty materialsCMOs
  5. China supply-chain exposureVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Some suppliers or sub-suppliers are based in China, increasing geopolitical and trade risk.

    Kohdistuu: Raw materials and reagents

Kysy Clarifolta: Faeth Therapeutics, Inc.

Kirjanpito

Harkinnanvaraiset erät
Acquired in-process research and development

The acquisition created a large fair-value charge for assets with no alternative future use.

Vaikutus: Can materially distort period-to-period comparability

Research and development expense timing

Trial, manufacturing, and outsourced development costs are recognized as incurred.

Vaikutus: Quarterly results can be volatile based on trial activity

Stock-based compensation

Equity awards and accelerated vesting can significantly increase reported expenses.

Vaikutus: Affects operating loss and non-cash expense profile

Fair value measurement

Acquired assets and related estimates depend on valuation assumptions.

Vaikutus: Can materially affect balance sheet and earnings

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Tyra Biosciences, Inc.

TYRA · Pharmaceutical Preparations

Verastem, Inc.

VSTM · Pharmaceutical Preparations

Aptevo Therapeutics Inc.

APVO · Pharmaceutical Preparations

Lantheus Holdings, Inc.

LNTH · In Vitro & In Vivo Diagnostic Substances

Bicycle Therapeutics plc

BCYC · Pharmaceutical Preparations

Whitehawk Therapeutics, Inc.

WHWK · Pharmaceutical Preparations

Päivitetty: 24.9.2026